Durect Corp
DRRX Real Time Price USDRecent trades of DRRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by DRRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Feb 11, 2008 Issue: Defense
-
$40,000 Aug 07, 2007 Issue: Defense
-
$40,000 Feb 12, 2007 Issue: Defense
-
$40,000 Aug 08, 2006 Issue: Defense
-
$40,000 Feb 14, 2006 Issue: Defense
Estimated quarterly lobbying spending
DRRX Revenue by Segment or Geography
New patents grants
-
Patent Title: Sustained release drug delivery systems with reduced impurities and related methods Oct. 03, 2023
-
Patent Title: Uses of oxygenated cholesterol sulfates (ocs) Mar. 28, 2023
-
Patent Title: Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same Dec. 20, 2022
-
Patent Title: Sustained release drug delivery systems with reduced impurities and related methods Aug. 02, 2022
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Mar. 29, 2022
-
Patent Title: Short duration depot formulations Nov. 23, 2021
-
Patent Title: Peroxide removal from drug delivery vehicle Aug. 10, 2021
-
Patent Title: Uses of oxygenated cholesterol sulfates (ocs) Sep. 29, 2020
-
Patent Title: Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same Sep. 01, 2020
-
Patent Title: Depot formulations Jun. 16, 2020
-
Patent Title: Depot formulations Jun. 02, 2020
-
Patent Title: Short duration depot formulations Nov. 12, 2019
-
Patent Title: Short duration depot formulations Nov. 12, 2019
-
Patent Title: Oral pharmaceutical dosage forms Jun. 25, 2019
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability May. 28, 2019
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Mar. 12, 2019
-
Patent Title: Oral pharamaceutical dosage forms Feb. 19, 2019
-
Patent Title: Short duration depot formulations Feb. 12, 2019
-
Patent Title: Depot formulations Jul. 24, 2018
-
Patent Title: Oral drug delivery system Mar. 20, 2018
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Mar. 06, 2018
-
Patent Title: Oral pharmaceutical dosage forms Feb. 06, 2018
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Jan. 02, 2018
-
Patent Title: Injectable controlled release composition comprising high viscosity liquid carrier Aug. 22, 2017
-
Patent Title: Oral pharmaceutical dosage forms May. 23, 2017
-
Patent Title: Oral pharmaceutical dosage forms Apr. 11, 2017
-
Patent Title: Sustained release small molecule drug formulation Mar. 21, 2017
-
Patent Title: Oral pharmaceutical dosage forms Mar. 14, 2017
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Feb. 21, 2017
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Feb. 21, 2017
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Jan. 31, 2017
-
Patent Title: Oral drug delivery system Dec. 13, 2016
-
Patent Title: Oral drug delivery system Jan. 12, 2016
-
Patent Title: Sustained release small molecule drug formulation Jun. 02, 2015
-
Patent Title: Oral drug delivery system Mar. 10, 2015
-
Patent Title: Transdermal delivery systems Feb. 17, 2015
-
Patent Title: Oral drug delivery system Feb. 10, 2015
-
Patent Title: Oral drug delivery system Feb. 03, 2015
-
Patent Title: Zero-order prolonged release coaxial implants Nov. 18, 2014
-
Patent Title: Sustained release small molecule drug formulation Oct. 07, 2014
-
Patent Title: Controlled delivery system Sep. 30, 2014
-
Patent Title: Injectable, non-aqueous suspension with high concentration of therapeutic agent Aug. 12, 2014
-
Patent Title: Controlled delivery system Jun. 17, 2014
-
Patent Title: Transdermal analgesic systems with reduced abuse potential Jun. 10, 2014
-
Patent Title: Polymeric device for controlled release of active agents May. 13, 2014
-
Patent Title: Polymeric devices for controlled release of active agents Feb. 11, 2014
-
Patent Title: Non-aqueous single phase vehicles and formulations utilizing such vehicles Jul. 30, 2013
-
Patent Title: Transdermal analgesic systems with reduced abuse potential May. 14, 2013
-
Patent Title: Oral drug delivery system Apr. 16, 2013
-
Patent Title: Oral pharmaceutical dosage forms Apr. 09, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to DRRX
Recent picks made for DRRX stock on CNBC
ETFs with the largest estimated holdings in DRRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DRRX stock a Buy, Sell, or Hold?
- What is the price target for $DRRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DRRX stock?
- Who owns the most shares of $DRRX stock?
- What funds own $DRRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DRRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.